Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 5/20 | 0.45 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335777 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL8886861 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL13363641 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL6166 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL767076 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL12070284 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL7087412 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| Water SCHEMBL7774670 | 0.98 | CTSK (0.53) | CTSKCTSSGABRB1GABRB2MAPT | |
| Water SCHEMBL8011422 | 0.98 | CTSK (0.53) | CTSKCTSSGABRB1GABRB2MAPT | |
| Water SCHEMBL766860 | 0.98 | CTSK (0.53) | CTSKCTSSGABRB1GABRB2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 604 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6372780-B1 | — | — | None | — | — | US | claimed |
| US-20190144406-A1 | CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING THE SAME | AVENTIS PHARMA SA (FR) | 2019-05-16 | — | — | US | claimed |
| EP-2791122-B1 | CRYSTALLINE FORM OF CABAZITAXEL AND PROCESS FOR PREPARING THE SAME | AVENTIS PHARMA SA (FR) | 2019-01-23 | — | — | EP | claimed |
| US-10160739-B2 | Crystalline forms of dimethoxy docetaxel and methods for preparing the same | AVENTIS PHARMA S.A. (FR) | 2018-12-25 | — | — | US | claimed |
| US-20180002302-A1 | CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING THE SAME | AVENTIS PHARMA S.A. (FR) | 2018-01-04 | — | — | US | claimed |
| EP-2247582-B1 | ANHYDROUS CRYSTALLINE FORM OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME | AVENTIS PHARMA SA (FR) | 2016-09-07 | — | — | EP | claimed |
| US-20140350272-A1 | CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING THE SAME | AVENTIS PHARMA S.A. (FR) | 2014-11-27 | — | — | US | claimed |
| US-20140343133-A1 | CRYSTALLINE FORM OF CABAZITAXEL AND PROCESS FOR PREPARING THE SAME | AVENTIS PHARMA S.A. (FR) | 2014-11-20 | — | — | US | claimed |
| US-8846959-B2 | Crystalline forms of dimethoxy docetaxel and methods for preparing the same | AVENTIS PHARMA SA (FR) | 2014-09-30 | — | — | US | claimed |
| EP-2719694-A1 | Anhydrous crystalline form of dimethoxy docetaxel and methods for preparing it | Aventis Pharma S.A. (FR) | 2014-04-16 | — | — | EP | claimed |
| US-5889043-A | Taxoids, preparation thereof and pharmaceutical Compositions containing same | RHONE-POULENC RORER S.A. (FR) | 1999-03-30 | — | — | US | claimed |
| US-5847170-A | Taxoids, their preparation and pharmaceutical compositions containing them | RHONE-POULENC RORER, S.A. (FR) | 1998-12-08 | — | — | US | claimed |
| EP-0876361-A1 | 4,10$g(b)-DIACETOXY-2$g(a)-BENZOYLOXY-5$g(b),20-EPOXY-1-HYDROXY-9-OXO-19-NOR-CYCLOPROPA G]TAX-11-ENE-13$g(a)-YL (2R,3S)-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DIHYDRATE, AND METHOD FOR PREPARING SAME | Aventis Pharma S.A. (FR) | 1998-11-11 | — | — | EP | claimed |
| EP-0770070-B1 | METHOD FOR PREPARING 4-ACETOXY-2ALPHA-BENZOYLOXY-5ALPHA,20-EPOXY-1,7BETA,10BETA-TRIHYDROXY-9-OXO-TAX-11-EN-13ALPHA-YL(2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE | RHONE POULENC RORER SA (FR) | 1998-09-30 | — | — | EP | claimed |
| US-5670536-A | Pharmaceutical composition based on taxoids | RHONE-POULENC RORER S.A. (FR) | 1997-09-23 | — | — | US | claimed |
| WO-1997021695-A1 | 4,10β-DIACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1-HYDROXY-9-OXO-19-NOR-CYCLOPROPA[G]TAX-11-ENE-13α-YL (2R,3S)-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DIHYDRATE, AND METHOD FOR PREPARING SAME | RHONE-POULENC RORER S.A. (FR) | 1997-06-19 | — | — | WO | claimed |
| EP-0770070-A1 | METHOD FOR PREPARING 4-ACETOXY-2ALPHA-BENZOYLOXY-5ALPHA,20-EPOXY-1,7BETA,10BETA-TRIHYDROXY-9-OXO-TAX-11-EN-13ALPHA-YL(2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE | Aventis Pharma S.A. (FR) | 1997-05-02 | — | — | EP | claimed |
| EP-0690852-B1 | METHOD FOR PURIFYING TAXOIDS | RHONE POULENC RORER SA (FR) | 1997-02-26 | — | — | EP | claimed |
| WO-1996001815-A1 | METHOD FOR PREPARING 4-ACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β,10β-TRIHYDROXY-9-OXO-TAX-11-EN-13α-YL(2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE | RHONE-POULENC RORER S.A. (FR) | 1996-01-25 | — | — | WO | claimed |
| EP-0630428-B1 | PROCESS FOR THE PREPARATION OF TAXANE DERIVATIVES | RHONE POULENC RORER SA (FR) | 1995-11-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343133-A1 | CRYSTALLINE FORM OF CABAZITAXEL AND PROCESS FOR PREPARING THE SAME | TUBA3C, TALDO1, TBCA | CTSK 1421/4885CTSS 1356/4885GABRB1 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.